Anebulo Pharmaceuticals, Inc. (ANEB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Anebulo Pharmaceuticals, Inc. (ANEB) is down 62.9% since the beginning of the year. At $0 per share, ANEB is trading 89.0% below its 52-week high of $3. Investors who bought $1,000 worth of ANEB shares 5 years ago would now be looking at an investment worth $51.

Anebulo Pharmaceuticals, Inc. (ANEB) has returned -62.86% so far this year and -65.27% over the past 12 months.

Based on dividend-adjusted daily data since May 7, 2021, ANEB's average daily return is +0.01%, while the average monthly return is +0.28%. At this rate, an investment would double in approximately 20.7 years.

Historically, 50% of months were positive and 50% were negative. The best month was Mar 2026 with a return of +175.0%, while the worst month was Feb 2026 at -65.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, ANEB closed higher 41% of trading days. The best single day was Jul 23, 2025 with a return of +82.0%, while the worst single day was Feb 6, 2026 at -39.1%.

Anebulo Pharmaceuticals, Inc. has an annualized alpha of -3.84%, beta of 0.43, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 10, 2021.

• This stock participated in 92.73% of S&P 500 Index downside but only -84.66% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.43 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ANEB ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Anebulo Pharmaceuticals, Inc. (ANEB) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Anebulo Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anebulo Pharmaceuticals, Inc. was 96.27%, occurring on Mar 3, 2026. The portfolio has not yet recovered.

The current Anebulo Pharmaceuticals, Inc. drawdown is 95.81%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Anebulo Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Anebulo Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.